Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cadrenal TherapeuticsCVKD -0.99%30 Quick Ratio is 2.68 as of Mar. 2026, which is 28% below its 10-year median of 3.71. GuruFocus rates CVKD with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 1,412 Biotechnology companies, Cadrenal Therapeutics ranks worse than 58.07% on this metric.
Cadrenal Therapeutics (NAS:CVKD) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Cadrenal Therapeutics Quick Ratio Related Terms
Cadrenal Therapeutics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Cadrenal Therapeutics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cadrenal Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cadrenal Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cadrenal Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Cadrenal Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Cadrenal Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cadrenal Therapeutics (CVKD) has a Quick Ratio of 2.68 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Cadrenal Therapeutics and its competitors. This is 28% below median its historical median of 3.71. Over the past decade, Cadrenal Therapeutics' Quick Ratio has ranged from 0.55 to 16.45. According to the industry distribution chart, Cadrenal Therapeutics ranks #820 out of 1412 companies in the Biotechnology industry, placing it in the top 58.1%.
Is Cadrenal Therapeutics' Quick Ratio too high?
Cadrenal Therapeutics' current Quick Ratio of 2.68 is 28% below median its 10-year median of 3.71. Over the past 10 years, this metric has ranged from a low of 0.55 to a high of 16.45. The Biotechnology industry median Quick Ratio is 3.57. Cadrenal Therapeutics' value of 2.68 is 24.8% below this industry median. Based on the distribution chart, Cadrenal Therapeutics ranks #820 out of 1412 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cadrenal Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Cadrenal Therapeutics' Quick Ratio compare to RVPH and IMNN?
According to the Biotechnology industry distribution chart, Cadrenal Therapeutics ranks #820 out of 1412 companies for Quick Ratio. This places Cadrenal Therapeutics in the lower half of its industry. The industry median Quick Ratio is 3.57. Cadrenal Therapeutics' value of 2.68 is 24.8% below this benchmark. Historically, Cadrenal Therapeutics' own Quick Ratio has ranged from 0.55 to 16.45 over the past decade. While the company's 10-year median is 3.71 vs. the industry median of 3.57, Cadrenal Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.57, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cadrenal Therapeutics's current Quick Ratio of 2.68 is 24.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Cadrenal Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cadrenal Therapeutics's current Quick Ratio is 2.68, which is 28% below median its own 10-year median of 3.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cadrenal Therapeutics stock overvalued right now?
Cadrenal Therapeutics (CVKD) has a current Quick Ratio of 2.68. The current Quick Ratio is 2.68, which is 28% below median its 10-year median of 3.71 and 24.8% below the Biotechnology industry median of 3.57. Cadrenal Therapeutics' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Cadrenal Therapeutics (CVKD), the current Quick Ratio is 2.68 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
30GF Score
Get the complete analysis for CVKD
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVKD has been successfully added to your 
